Cartilage oligomeric matrix protein increases in serum after the start of growth hormone treatment in prepubertal children
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Bjarnason, RAndersson, B
Kim, H S
Olsson, B
Swolin-Eide, D
Wickelgren, R
Kriström, B
Carlsson, B
Albertsson-Wikland, K
Carlsson, L M S
Issue Date
2004
Metadata
Show full item recordCitation
J. Clin. Endocrinol. Metab. 2004, 89(10):5156-60Abstract
Both GH and IGF-I stimulate bone growth, but the molecular mechanisms mediating their effects on the growth plate are not fully understood. We measured gene expression by microarray analysis in primary cultured human chondrocytes treated with either GH or IGF-I. One of the genes found to be up-regulated by both GH and IGF-I was that encoding cartilage oligomeric matrix protein (COMP). This protein is predominantly found in the extracellular matrix of cartilage. Mutations in the COMP gene have been associated with syndromes of short stature. To verify that COMP is regulated by GH in vivo, we measured COMP levels in serum in short children treated with GH. The study included 113 short prepubertal children (14 girls and 99 boys) with a mean (+/- sd) age of 8.84 +/- 2.76 yr, height sd score of -2.74 +/- 0.67, and IGF-I sd score of -1.21 +/- 1.07 at the start of GH administration. Serum levels of COMP were 1.58 +/- 0.28, 1.83 +/- 0.28 (P < 0.0001), 1.91 +/- 0.28 (P < 0.0001), 1.78 +/- 0.28 (P < 0.001), and 1.70 +/- 0.24 (P < 0.05) microg/ml at baseline and after 1 wk and 1, 3, and 12 months, respectively.In conclusion, we have demonstrated that COMP expression is up-regulated by both GH and IGF-I in primary cultured human chondrocytes. Furthermore, serum levels of COMP increase after the start of GH treatment in short children.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://jcem.endojournals.org/cgi/content/full/89/10/5156ae974a485f413a2113503eed53cd6c53
10.1210/jc.2004-0587
Scopus Count
Collections
Related articles
- Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
- Authors: Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K
- Issue date: 1996 Nov
- Growth hormone (GH)-binding protein in prepubertal short children born small for gestational age: effects of growth hormone treatment. Swedish Study Group for Growth Hormone Treatment.
- Authors: Boguszewski M, Bjarnason R, Rosberg S, Carlsson LM, Albertsson-Wikland K
- Issue date: 1997 Apr
- Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
- Authors: de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG
- Issue date: 1999 May
- Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
- Authors: Barreca A, Bozzola M, Cesarone A, Steenbergh PH, Holthuizen PE, Severi F, Giordano G, Minuto F
- Issue date: 1998 Oct
- The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature.
- Authors: Bouhours-Nouet N, Gatelais F, Boux de Casson F, Rouleau S, Coutant R
- Issue date: 2007 Feb